Novartis announces FDA approval of Xolair(R) (omalizumab) for adults with nasal polyps

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in two formulations, continuing to build on the medicine's 1... Biopharmaceuticals, FDA Novartis, Xolair, omalizumab, nasal polyps
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news